



Drug Quantity Management – Per Rx Antivirals – Famciclovir tablets (generic only)

Table of Contents

National Formulary Medical Necessity	1
Conditions Not Covered.....	2
Background.....	2
References	5
Revision History.....	5

Product Identifier(s)

Effective 1/1/23 to 2/6/23: 108851
Effective 2/7/23: 34093

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of famciclovir. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Drug Quantity Limits

Product	Strength and Form	Maximum Quantity per Rx
Famciclovir tablets (generic only)	125 mg tablets	21 tablets
	250 mg tablets	60 tablets
	500 mg tablets	21 tablets

Criteria

Cigna covers quantities as medically necessary when the following criteria are met:

famciclovir 125 mg tablets

1. If the individual meets the following criteria (A and B), approve 60 tablets per dispensing:
 - A) The medication is for chronic suppression or prevention of recurrent genital herpes; AND
 - B) Individual has reduced renal function.
2. If the medication is being requested for an ophthalmic infection, approve the quantity requested for a 30-day supply per dispensing.

famciclovir 250 mg tablets

1. If the medication is being requested for an ophthalmic infection, approve the quantity requested for a 30-day supply per dispensing.

famciclovir 500 mg tablets

1. If the medication is being requested for the chronic suppression or prevention of mucocutaneous herpes (genital, perianal, oral) in an immunocompromised individual, approve 60 tablets per dispensing.
2. If the medication is being requested for the treatment of mucocutaneous herpes (genital, perianal, oral) in an immunocompromised individual, approve 60 tablets per dispensing.
3. If the medication is being requested for an ophthalmic infection, approve the quantity requested for a 30-day supply per dispensing.
4. If the medication is being requested for the treatment of varicella zoster virus infection in immunocompromised individuals, approve up to 90 tablets per dispensing.
5. If the medication is being requested for the treatment of acute local dermatomal herpes zoster in an immunocompromised individual, approve up to 90 tablets per dispensing.

Conditions Not Covered

Any other exception is considered not medically necessary.

Background

Overview

Famciclovir is an orally administered prodrug of the anti-alpha herpes viral agent penciclovir.¹ It is indicated in the following instances:

- Immunocompetent Adults:
 - Treatment of recurrent **herpes labialis** (cold sores).
 - Treatment and chronic suppressive therapy of recurrent episodes of **genital herpes**.
 - Treatment of **herpes zoster**.
- Human Immunodeficiency Virus (HIV)-Infected Adults:
 - Treatment of recurrent episodes of **orolabial or genital herpes**.

Dosing/Availability

Famciclovir is available as 125 mg, 250 mg, and 500 mg tablets.¹ The 125 mg tablet is available for dosage reductions in renal impairment. Manufacturer recommended dosing is provided in Table 1. The maximum number of tablets needed per course of treatment is 21 tablets.

Table 1. FDA-Approved Famciclovir Dosing.¹

Indication	Normal dosage regimen	Dosing Adjustments			
		CrCl 40 to 59 mL/min	CrCl 20 to 39 mL/min	CrCl < 20 mL/min	Hemodialysis
Immunocompetent Adults					
Recurrent herpes labialis (cold sores)	1,500 mg as a single dose	750 mg as a single dose	500 mg as a single dose	250 mg as a single dose	250 mg single dose following dialysis
Recurrent genital herpes	1 gram BID for 1 day	500 mg every 12 hours for 1 day	500 mg as a single dose	250 mg as a single dose	250 mg single dose following dialysis
Suppression of recurrent genital herpes	250 mg BID for up to 1 year	250 mg every 12 hours for up to 1 year	125 mg every 12 hours for up to 1 year	125 mg every 24 hours for up to 1 year	125 mg following each dialysis for up to 1 year
Herpes zoster (shingles)	500 mg every 8 hours for 7 days	500 mg every 12 hours for 7 days	500 mg every 24 hours for 7 days	250 mg every 24 hours for 7 days	250 mg following each dialysis for 7 days
HIV-infected Adults					
Recurrent orolabial and genital herpes infection	500 mg BID for 7 days	500 mg every 12 hours for 7 days	500 mg every 24 hours for 7 days	250 mg every 24 hours for 7 days	250 mg following each dialysis for 7 days

CrCl – Creatinine clearance; BID – Twice daily; HIV – human immunodeficiency virus.

Literature and guidelines support the use of famciclovir for several indications related to reactivation to latent varicella (chickenpox) virus.

For the treatment of an initial episode of genital herpes in immunocompetent patients, the Centers for Disease Control and Prevention (CDC) guidelines recommend famciclovir 250 mg three times daily (TID) for 7 to 10 days.² For immunocompetent individuals with recurrent genital HSV the CDC outlines the following treatment regimens: 1 gram twice daily (BID) for 1 day (FDA-approved dose), 500 mg one time followed by 250 mg BID for 5 days, or 125 mg BID for 5 days.²

Certain immunocompetent patients with herpes zoster will present with ocular, otic, or neurologic manifestations. In these situations, patients may require intravenous (IV) and/or prolonged therapy.¹¹ Herpes zoster ophthalmicus is a serious sight-threatening condition associated with varicella zoster virus reactivation within the trigeminal ganglion. Patients can develop conjunctivitis, episcleritis, keratitis, and/or iritis. The standard approach to herpes zoster ophthalmicus includes oral antiviral therapy (acyclovir, valacyclovir, or famciclovir) to limit viral replication, and the use adjunctive topical steroid drops to reduce the inflammatory response and control immune-associated keratitis and iritis. IV acyclovir (10 mg/kg TID for 7 days) should be administered if the patient is immunocompromised or requires hospitalization for sight-threatening disease.

For Bell's Palsy, famciclovir 250 mg TID for 5 to 7 days in combination with a corticosteroid has been used.⁵⁻⁹ The major otologic complication of varicella zoster reactivation is Ramsay Hunt syndrome, which includes the triad of ipsilateral facial paralysis, ear pain, and vesicles in the auditory canal and auricle.⁷ Valacyclovir (1 g TID) for 7 to 10 days with and prednisone, (not famciclovir) is used. In severe cases (vertigo, tinnitus, or hearing loss), IV therapy can be initiated, and the patient can then be transitioned to an oral antiviral agent when the lesions begin to crust.

For adults with human immunodeficiency virus (HIV), the Department of Health and Human Services (DHHS) guidelines on opportunistic infections recommend that orolabial herpes simplex virus (HSV) be treated with famciclovir 500 mg twice daily (BID) for 5 to 10 days; first episodes of genital HSV should be treated with famciclovir 500 mg BID for 7 to 10 days and recurrent episodes for 5 to 10 days.³ Severe mucocutaneous HSV lesions respond best to initial treatment with IV therapy; once lesions regress, patients can be switched to oral famciclovir and continued until lesions have completely healed. Suppressive therapy is effective in preventing recurrences of HSV lesions and is preferred for patients who have severe or frequent recurrences or who want to

minimize the frequency of recurrences. Suppressive therapy for HSV with famciclovir 500 mg BID may be continued indefinitely, without regard to improved CD4 count, although the need for continued therapy should be addressed on an annual basis, particularly if immune reconstitution has occurred.

For uncomplicated varicella, famciclovir (500 mg TID), initiated as early as possible after lesion onset and continued for 5 to 7 days is a preferred regimen.³ For individuals with severe or complicated varicella, IV therapy is recommended; if no evidence of visceral involvement is apparent, it is recommended to switch to oral antiviral therapy after the patient has defervesced (famciclovir 500 mg TID, optimal duration is not cited). For herpes zoster virus, antiviral therapy with famciclovir 500 mg TID should be instituted as soon as possible and continued for 7 to 10 days, although longer durations of therapy should be considered if lesions resolve slowly.

For acute localized dermatomal herpes zoster in individuals with HIV famciclovir 500 mg TID for 7 to 10 days is recommended, although longer durations of therapy should be considered if lesions resolve slowly.³ If cutaneous lesions are extensive or if visceral involvement is suspected, IV acyclovir should be initiated and continued until clinical improvement is evident. A switch from IV acyclovir to oral antiviral therapy (famciclovir 500 mg TID to complete a 10 to 14 day treatment course) is reasonable when formation of new cutaneous lesions has ceased and the signs and symptoms of visceral varicella zoster virus infection are improving. For herpes zoster ophthalmitis, following IV acyclovir, patients are switched to oral therapy which can include famciclovir 500 mg TID to complete a 10 to 14 day course of therapy.

Table 2. DHHS Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV.³

Indication	Usual Dose	Renal Dose Adjustment	Duration
HSV			
Orolabial	Famciclovir 500 mg BID	CrCl 20 to 39 mL/min: 500 mg Q24 hours CrCl < 20 mL/min: 250 mg Q24 hours HD: 250 mg on HD days.	5 to 10 days
Genital – First Episode			7 to 10 days
Genital – Recurrent Episode			5 to 10 days
Severe Mucocutaneous			Until lesions are completely healed.
Chronic Suppressive Therapy			Indefinite (evaluate annually)
Varicella Zoster			
Uncomplicated Primary Varicella Infection (Chickenpox)	Famciclovir 500 mg TID	CrCl 20 to 39 mL/min: 500 mg Q24 hours CrCl < 20 mL/min: 250 mg Q24 hours HD: 250 mg on HD days.	5 to 7 days
Severe or Complicated varicella			Optimal duration not cited (following IV therapy).
Herpes Zoster (Shingles) [acute localized dermatonal]			7 to 10 days; consider longer therapy if lesions resolve slowly. Patients continuing from IV therapy should complete a 10 to 14 day course of therapy.
Herpes Zoster Ophthalmitis – Extensive Cutaneous Lesion or Visceral Involvement			10 to 14 days

DHHS – Department of Health and Human Services; HIV – Human Immunodeficiency Virus; BID – Twice daily; CrCl – Creatinine clearance; Q24 – Every 24; HD – Hemodialysis; TID – Three times daily; IV – Intravenous.

There are no dosage forms of famciclovir available to accommodate pediatric patients who cannot swallow tablets. According to the guidelines for the treatment of opportunistic infections in HIV-infected children, famciclovir 250 mg BID for 5 to 14 days is used to treat genital HSV episodes.⁴ Children who have frequent, severe, or troubling recurrences of mucocutaneous HSV (four to six severe episodes a year) can be given daily prophylaxis with oral famciclovir (500 mg BID).⁴ For the treatment of recurrent herpes labialis in children old enough for adult dosing, famciclovir 1 g BID for 1 day is an option. Recurrent genital HSV in children can be treated with famciclovir 1 g BID for two doses.

References

1. Famciclovir [prescribing information]. North Wales, PA: Teva Pharmaceuticals; January 2019.
2. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2021. *MMWR*. 2021;70(4):1-192. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344968/pdf/rr7004a1.pdf>. Accessed on March 23, 2022.
3. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Updated February 17, 2022. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf. Accessed March 22, 2022.
4. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Updated January 24, 2022. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/OI_Guidelines_Pediatrics.pdf. Accessed March 22, 2022.
5. Aizman A, Johnson MW, Elner SG. Treatment of acute retinal necrosis syndrome with oral antiviral medications. *Ophthalmology*. 2007;114:307-312.
6. Tibbetts, MD, Shah CP, Young LH, et al. Treatment of acute retinal necrosis. *Ophthalmology*. 2010;117:818-824.
7. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2010. Available at: <http://www.clinicalpharmacology-ip.com/Default.aspx>. Accessed on March 23, 2022. Search terms: famciclovir.
8. Albrecht MA. Treatment of herpes zoster in the immunocompetent host. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed on March 25, 2022.
9. Pergam SA and Limaye AP on behalf of the American Society of Transplantation Infectious Diseases Community of Practice. Varicella zoster virus in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community. *Clinical Transplantation*. 2019;33:e13622.

Revision History

Type of Revision	Summary of Changes	Approval Date
Annual Revision	<p>Famciclovir 500 mg tablets.</p> <p>Bell's palsy was removed as a condition for overrides (previously up to 30 tablets per dispensing was approved). This condition is covered by the current limits.</p> <p>Ramsy Hunt was removed as a condition for overrides (previously up to 30 tablets per dispensing was approved). This condition is not generally treated with famciclovir.</p> <p>"Primary" was removed for the override of primary varicella zoster virus in immunocompromised patients. The quantity of the override was updated to 90 tablets per dispensing (previously 30 tablets per dispensing).</p> <p>For acute local dermatomal herpes zoster in an immunocompromised patient, the override was updated to 90 tablets per dispensing (previously 42 tablets per dispensing).</p>	04/06/2022

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc. and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2023 Cigna.